PL369763A1 - Związki heterocykliczne do zastosowania w leczeniu zaburzeń układu moczowego - Google Patents

Związki heterocykliczne do zastosowania w leczeniu zaburzeń układu moczowego

Info

Publication number: PL369763A1
Authority: PL; Poland
Prior art keywords: disorders; treatment; urinary tract; heterocyclic compounds; heterocyclic
Prior art date: 2001-10-05

Application number

PL02369763A

Other languages

English (en)

Inventor

Amedeo Leonardi

Gianni Motta

Carlo Riva

Rodolfo Testa

Jeff W. Corbett

Original Assignee

Recordati S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-05

Filing date

2002-10-07

Publication date

2005-05-02

2002-10-07 Application filed by Recordati S.A. filed Critical Recordati S.A.

2005-05-02 Publication of PL369763A1 publication Critical patent/PL369763A1/pl

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000035475 disorder Diseases 0.000 title 1
150000002391 heterocyclic compounds Chemical class 0.000 title 1
210000001635 urinary tract Anatomy 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

PL02369763A 2001-10-05 2002-10-07 Związki heterocykliczne do zastosowania w leczeniu zaburzeń układu moczowego PL369763A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2001MI002060A ITMI20012060A1 (it)	2001-10-05	2001-10-05	Nuovi eterocilcli n-acilati

Publications (1)

Publication Number	Publication Date
PL369763A1 true PL369763A1 (pl)	2005-05-02

Family

ID=11448476

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02369763A PL369763A1 (pl)	2001-10-05	2002-10-07	Związki heterocykliczne do zastosowania w leczeniu zaburzeń układu moczowego

Country Status (32)

Country	Link
US (2)	US20030162777A1 (pl)
EP (1)	EP1432701B1 (pl)
JP (1)	JP2005508952A (pl)
KR (1)	KR20040048930A (pl)
CN (1)	CN1564820A (pl)
AP (1)	AP1705A (pl)
AR (1)	AR036743A1 (pl)
AT (1)	ATE313540T1 (pl)
AU (1)	AU2002346979B9 (pl)
BR (1)	BR0213067A (pl)
CA (1)	CA2458456A1 (pl)
CO (1)	CO5570679A2 (pl)
CY (1)	CY1104991T1 (pl)
DE (1)	DE60208221T2 (pl)
DK (1)	DK1432701T3 (pl)
EA (1)	EA200400507A1 (pl)
EC (1)	ECSP045095A (pl)
ES (1)	ES2253568T3 (pl)
HR (1)	HRP20040392A2 (pl)
HU (1)	HUP0401598A2 (pl)
IT (1)	ITMI20012060A1 (pl)
MA (1)	MA27067A1 (pl)
MX (1)	MXPA04002962A (pl)
NO (1)	NO20041833L (pl)
NZ (1)	NZ532511A (pl)
OA (1)	OA12663A (pl)
PL (1)	PL369763A1 (pl)
SI (1)	SI1432701T1 (pl)
TN (1)	TNSN04053A1 (pl)
WO (1)	WO2003031436A1 (pl)
YU (1)	YU27204A (pl)
ZA (1)	ZA200403356B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR035521A1 (es) *	2000-12-22	2004-06-02	Lundbeck & Co As H	Derivados de 3-indolina y composicion farmaceutica que los comprende
US7504395B2 (en) *	2001-07-20	2009-03-17	Psychogenics, Inc.	Treatment for attention-deficit hyperactivity disorder
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati
US20040058962A1 (en) *	2002-06-14	2004-03-25	Amedeo Leonardi	Phenylalkylamines and pyridylalkylamines
US20040215284A1 (en) *	2003-01-30	2004-10-28	Recordati S.A.	Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
UY28538A1 (es) *	2003-09-26	2005-04-29	Vertex Pharma	Derivados de fenil-piperazina como moduladores de receptores muscarínicos
RU2006124559A (ru) *	2003-12-09	2008-01-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Производные нафтиридина и применение указанных производныхых в качестве модуляторов мускариновых рецепторов
US20050165025A1 (en) *	2004-01-22	2005-07-28	Recordati Ireland Ltd.	Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7553967B2 (en) *	2004-03-12	2009-06-30	Wyeth	1,2-Dihydroquinoline derivatives and method for using the same to treat HIV infections
US7582634B2 (en)	2005-02-18	2009-09-01	Wyeth	7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en)	2005-02-18	2009-05-26	Wyeth	4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en)	2005-02-18	2009-05-19	Wyeth	Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en)	2005-05-18	2009-05-12	Wyeth	Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en)	2005-05-26	2009-09-01	Wyeth	Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
DE102005027168A1 (de) *	2005-06-13	2006-12-14	Merck Patent Gmbh	Tetrahydrochinoline
WO2007134149A2 (en)	2006-05-11	2007-11-22	Janssen Pharmaceutica N.V.	3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
US7928238B2 (en)	2006-05-11	2011-04-19	Janssen Pharmaceutica Nv	1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors
TW200811158A (en)	2006-06-27	2008-03-01	Sanofi Aventis	Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application
PE20080344A1 (es)	2006-06-27	2008-06-09	Sanofi Aventis	Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
FR2902790A1 (fr) *	2006-06-27	2007-12-28	Sanofi Aventis Sa	Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique
KR20090030345A (ko)	2006-07-19	2009-03-24	더 오하이오 스테이트 유니버시티 리서치 파운데이션	선택적인 안드로겐 수용체 모듈레이터, 그 유사체와 유도체, 및 그의 용도
JP5323834B2 (ja) *	2007-08-17	2013-10-23	エルジー・ライフ・サイエンシーズ・リミテッド	細胞壊死阻害剤としてのインドール化合物
CA2722340A1 (en) *	2008-04-24	2009-10-29	Marc Diamond	Small-molecule inhibitors of the androgen receptor
FR2969151B1 (fr) *	2010-12-17	2016-11-04	Oreal	Derives du 4-amino et leur utilisation pour la coloration d'oxydation des fibres keratiniques.
WO2015035278A1 (en) *	2013-09-09	2015-03-12	Bristol-Myers Squibb Company	RORγ MODULATORS
EP3046906B1 (en) *	2013-09-20	2017-08-16	Bristol-Myers Squibb Company	Ror gamma modulators
AR107032A1 (es) *	2015-12-09	2018-03-14	Padlock Therapeutics Inc	Inhibidores bicíclicos de pad4
CN108299397B (zh) *	2018-03-21	2019-01-29	佳木斯大学附属第一医院	一种用于降血压的活性药物及其制备方法
WO2025217141A1 (en) *	2024-04-09	2025-10-16	Enanta Pharmaceuticals, Inc.	Pharmaceutical compounds and compositions as modulators of mas-related g-protein receptor x2

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1027611A (en) *	1962-01-04	1966-04-27	May & Baker Ltd	Phenoxy- and phenylthio-alkylamines and acid addition salts thereof
GB1166538A (en) *	1967-06-10	1969-10-08	Pfizer Ltd	Substituted Tetrahydroquinolines
US3983121A (en) *	1974-07-01	1976-09-28	Council Of Scientific And Industrial Research	1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US4011324A (en) *	1976-01-20	1977-03-08	Pfizer Inc.	Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4461896A (en) *	1979-02-07	1984-07-24	Norwich Eaton Pharmaceuticals, Inc.	1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids
CH653021A5 (fr) *	1981-04-24	1985-12-13	Delalande Sa	Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
US4585773A (en) *	1984-07-11	1986-04-29	Bristol-Myers Company	Isoindolinyl-alkyl-piperazines
DE3586794T2 (de) *	1984-12-21	1993-05-27	Duphar Int Res	Arzneimittel mit psychotroper wirkung.
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5641504A (en) *	1988-06-09	1997-06-24	Alza Corporation	Skin permeation enhancer compositions using glycerol monolinoleate
IE920040A1 (en) *	1991-01-09	1992-07-15	Alza Corp	Bioerodible devices and compositions for diffusional release¹of agents
US5443459A (en) *	1991-01-30	1995-08-22	Alza Corporation	Osmotic device for delayed delivery of agent
JPH05117276A (ja) *	1991-10-23	1993-05-14	Sumitomo Pharmaceut Co Ltd	新規な３環性キノキサリンジオン誘導体
US5629019A (en) *	1992-02-27	1997-05-13	Alza Corporation	Formulations with hydrophobic permeation enhancers
JP3786684B2 (ja) *	1992-05-13	2006-06-14	アルザ・コーポレーション	オキシブチニンの経皮投与
US5512293A (en) *	1992-07-23	1996-04-30	Alza Corporation	Oral sustained release drug delivery device
US5573776A (en) *	1992-12-02	1996-11-12	Alza Corporation	Oral osmotic device with hydrogel driving member
US5533971A (en) *	1993-09-03	1996-07-09	Alza Corporation	Reduction of skin irritation during electrotransport
IT1270993B (it) *	1994-03-18	1997-05-26	Recordati Chem Pharm	Derivati chinzolilamminici attivi come alfa-antagonisti
FR2729144A1 (fr) *	1995-01-06	1996-07-12	Smithkline Beecham Lab	Nouvelles diamines, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu' agents anti-arythmiques
US5859014A (en) *	1995-06-09	1999-01-12	Syntex (U.S.A.) Inc.	Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
US5780058A (en) *	1995-07-21	1998-07-14	Alza Corporation	Oral delivery of discrete units
US6096339A (en) *	1997-04-04	2000-08-01	Alza Corporation	Dosage form, process of making and using same
CA2239227C (en) *	1996-10-01	2007-10-30	Kyowa Hakko Kirin Co., Ltd.	Nitrogen-containing heterocyclic compounds
EP0846683B1 (en) *	1996-12-03	2001-09-19	F. Hoffmann-La Roche Ag	4-Hydroxy-piperidine derivatives
CA2220649C (en) *	1996-12-03	2007-02-13	F. Hoffmann-La Roche Ag	4-hydroxy-piperidine derivatives
US6281227B1 (en) *	1996-12-13	2001-08-28	Aventis Pharma Deutschland Gmbh	Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
JP2002512597A (ja) *	1996-12-20	2002-04-23	アルザコーポレイション	注射可能な貯留槽ゲル組成物およびこの組成物の製造方法
US6169086B1 (en) *	1997-01-27	2001-01-02	Daiichi Pharmaceutical Co., Ltd.	Pyrazole derivatives
IT1293804B1 (it) *	1997-08-01	1999-03-10	Recordati Chem Pharm	Diarilalchilpiperazine attive sulle basse vie urinarie
AU9256498A (en) *	1997-08-01	1999-02-22	Recordati S.A. Chemical And Pharmaceutical Company	1,4-disubstituted piperazines
US6039977A (en) *	1997-12-09	2000-03-21	Alza Corporation	Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
EP1069111A4 (en) *	1998-03-26	2001-06-06	Shionogi & Co	INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY
US6174547B1 (en) *	1999-07-14	2001-01-16	Alza Corporation	Dosage form comprising liquid formulation
US6306861B1 (en) *	1999-07-30	2001-10-23	Recordati S.A. Chemical And Pharmaceutical Company	Thienopyrancecarboxamide derivatives
US6365591B1 (en) *	1999-10-18	2002-04-02	Recordati, S.A., Chemical And Pharmacueticals Company	Isoxazolecarboxamide derivatives
US6403594B1 (en) *	1999-10-18	2002-06-11	Recordati, S.A. Chemical And Pharmaceutical Company	Benzopyran derivatives
AR035521A1 (es) *	2000-12-22	2004-06-02	Lundbeck & Co As H	Derivados de 3-indolina y composicion farmaceutica que los comprende
US20030060513A1 (en) *	2001-09-27	2003-03-27	Arneric Stephen P.	Pharmaceutical composition
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati

2001
- 2001-10-05 IT IT2001MI002060A patent/ITMI20012060A1/it unknown
2002
- 2002-10-04 AR ARP020103760A patent/AR036743A1/es not_active Application Discontinuation
- 2002-10-07 CA CA002458456A patent/CA2458456A1/en not_active Abandoned
- 2002-10-07 EP EP02782863A patent/EP1432701B1/en not_active Expired - Lifetime
- 2002-10-07 EA EA200400507A patent/EA200400507A1/ru unknown
- 2002-10-07 DK DK02782863T patent/DK1432701T3/da active
- 2002-10-07 DE DE60208221T patent/DE60208221T2/de not_active Expired - Fee Related
- 2002-10-07 PL PL02369763A patent/PL369763A1/pl not_active Application Discontinuation
- 2002-10-07 AP APAP/P/2004/002997A patent/AP1705A/en active
- 2002-10-07 SI SI200230244T patent/SI1432701T1/sl unknown
- 2002-10-07 KR KR10-2004-7004948A patent/KR20040048930A/ko not_active Withdrawn
- 2002-10-07 US US10/266,104 patent/US20030162777A1/en not_active Abandoned
- 2002-10-07 OA OA1200400088A patent/OA12663A/en unknown
- 2002-10-07 YU YU27204A patent/YU27204A/sh unknown
- 2002-10-07 HU HU0401598A patent/HUP0401598A2/hu unknown
- 2002-10-07 AU AU2002346979A patent/AU2002346979B9/en not_active Ceased
- 2002-10-07 US US10/266,088 patent/US20030181446A1/en not_active Abandoned
- 2002-10-07 NZ NZ532511A patent/NZ532511A/en unknown
- 2002-10-07 ES ES02782863T patent/ES2253568T3/es not_active Expired - Lifetime
- 2002-10-07 WO PCT/EP2002/011282 patent/WO2003031436A1/en not_active Ceased
- 2002-10-07 CN CNA028197283A patent/CN1564820A/zh active Pending
- 2002-10-07 HR HR20040392A patent/HRP20040392A2/hr not_active Application Discontinuation
- 2002-10-07 MX MXPA04002962A patent/MXPA04002962A/es unknown
- 2002-10-07 JP JP2003534419A patent/JP2005508952A/ja not_active Withdrawn
- 2002-10-07 AT AT02782863T patent/ATE313540T1/de not_active IP Right Cessation
- 2002-10-07 BR BR0213067-0A patent/BR0213067A/pt not_active IP Right Cessation
2004
- 2004-03-11 MA MA27571A patent/MA27067A1/fr unknown
- 2004-04-02 TN TNP2004000053A patent/TNSN04053A1/en unknown
- 2004-05-04 ZA ZA200403356A patent/ZA200403356B/en unknown
- 2004-05-04 NO NO20041833A patent/NO20041833L/no not_active Application Discontinuation
- 2004-05-04 CO CO04040886A patent/CO5570679A2/es not_active Application Discontinuation
- 2004-05-05 EC EC2004005095A patent/ECSP045095A/es unknown
2006
- 2006-03-03 CY CY20061100304T patent/CY1104991T1/el unknown

Also Published As

Publication number	Publication date
DK1432701T3 (da)	2006-05-08
US20030181446A1 (en)	2003-09-25
JP2005508952A (ja)	2005-04-07
ATE313540T1 (de)	2006-01-15
NO20041833L (no)	2004-07-05
ZA200403356B (en)	2004-11-08
SI1432701T1 (sl)	2006-04-30
US20030162777A1 (en)	2003-08-28
EP1432701A1 (en)	2004-06-30
AP2004002997A0 (en)	2004-03-31
HUP0401598A2 (hu)	2004-12-28
AU2002346979B9 (en)	2006-03-02
WO2003031436A1 (en)	2003-04-17
TNSN04053A1 (en)	2006-06-01
CN1564820A (zh)	2005-01-12
ITMI20012060A1 (it)	2003-04-05
WO2003031436A8 (en)	2004-05-27
DE60208221T2 (de)	2006-08-03
AP1705A (en)	2007-01-02
BR0213067A (pt)	2004-09-28
CY1104991T1 (el)	2010-03-03
EA200400507A1 (ru)	2004-10-28
HRP20040392A2 (en)	2004-10-31
ES2253568T3 (es)	2006-06-01
ECSP045095A (es)	2004-08-27
CA2458456A1 (en)	2003-04-17
KR20040048930A (ko)	2004-06-10
MXPA04002962A (es)	2005-06-20
CO5570679A2 (es)	2005-10-31
AR036743A1 (es)	2004-09-29
YU27204A (sh)	2006-08-17
HK1067362A1 (en)	2005-04-08
AU2002346979B2 (en)	2005-09-29
NZ532511A (en)	2005-10-28
OA12663A (en)	2006-06-19
DE60208221D1 (de)	2006-01-26
EP1432701B1 (en)	2005-12-21
MA27067A1 (fr)	2004-12-20

Legal Events

Date	Code	Title	Description
2011-03-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
SI1432701T1 (sl)	2006-04-30	Uporaba heterociklicnih spojin pri zdravljenju bolezni urinarnega trakta
IL209842A0 (en)	2011-02-28	Compounds for the treatment of metabolic disorders
IL173439A0 (en)	2006-06-11	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
IL159771A0 (en)	2004-06-20	Combinations for the treatment of inflammatory disorders
IL159344A0 (en)	2004-06-01	Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
PL362711A1 (pl)	2004-11-02	Pochodne morfolinoacetamidu do leczenia chorób zapalnych
IL162485A0 (en)	2005-11-20	Compounds for the treatment of inflammatory disorders
IL183656A0 (en)	2007-09-20	Indenyl derivatives and use thereof for the treatment of neurological disorders
IL151890A0 (en)	2003-04-10	Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
PT1487828E (pt)	2009-01-06	Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
HUP0402421A3 (en)	2008-02-28	Composition inhibiting matrix-metalloproteinases for the treatment of neoplastic diseases
IL176968A0 (en)	2006-12-10	Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
IL158050A0 (en)	2004-03-28	Use of selective cox-2 inhibitors for the treatment of urinary incontinence
PL357812A1 (pl)	2004-07-26	Pochodne hydroksyfenylopiperazynylometylobenzamidu do leczenia bólu
GB0213869D0 (en)	2002-07-31	The treatment of pain
HUP0500162A2 (en)	2006-08-28	Heterocyclic compounds useful for preventives/remedies for urinary disturbance and pharmaceutical compounds thereof
PL375564A1 (pl)	2005-11-28	Podstawione 5-chroman-5-ylo-etyloaminy i ich zastosowanie do leczenia jaskry
IL150290A0 (en)	2002-12-01	The use of mirtazapine for the treatment of sleep disorders
IL161748A0 (en)	2005-11-20	New use for the treatment of gastroesophageal reflux
IL160852A0 (en)	2004-08-31	Pharmaceutical compositions for the treatment of urinary disorders
IL162776A0 (en)	2005-11-20	2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
IL175412A0 (en)	2006-09-05	Use of specific histones for the treatment of parasitic diseases
PT1698338E (pt)	2008-06-03	S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
AU2003283153A8 (en)	2004-02-25	Pharmaceutical compositions for the treatment of urinary incontinence
EP1377289A4 (en)	2008-09-10	HETEROCYCLIC COMPOUNDS WITH THERAPEUTIC USE